Results 61 to 70 of about 6,317 (201)

Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis [PDF]

, 2019
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation.
Castro, Mario, et al,, Maspero, Jorge F
core   +1 more source

Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease:A Post Hoc Analysis [PDF]

, 2023
Exacerbations in chronic obstructive pulmonary disease (COPD), which tend to occur in clusters and increase with disease severity, come with high societal and economic burdens.
Agustí, Alvar, Bafadhel, Mona, Criner, Gerard J., Jison, Maria, Licaj, Idlir, Martin, Ubaldo J., Psallidas, Ioannis, Saraiva, Gabriela Luporini, Singh, Dave, Song, Yue, Söderström, Johan   +10 more
core   +1 more source

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

Allergy, EarlyView.
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier, Z. Abdul Hameed Ansari, A. H. Abdul Latiff, M. M. Abuzakouk, M. S. Agcaoili‐De Jesus, R. C. Agondi, M. Al‐Ahmad, A. A. Alangari, H. Alhameli, C. D. Alonso Bello, S. Alshareef, S. Al‐Tamemi, S. Altrichter, H. Al Wahshi, S. Aquilina, M. Araújo, R. Arnaout, R. Asero, B. Ballmer‐Weber, C. Bangert, A. Bauer, M. Ben‐Shoshan, J. Bernstein, C. Bindslev‐Jensen, M. Bizjak, I. Boccon‐Gibod, H. Bonnekoh, L. Bouillet, K. Brockow, Z. Brzoza, M. Bulatović Ćalasan, A. Bulkhi, T. Buttgereit, A. Bygum, T. Caballero, O. Calderon, R. Campos, M. Cancian, E. Carne, M. A. Castor, I. Cerecedo, T. Çetinarslan, I. Cherrez‐Ojeda, N. Chkhikvadze, H. J. Chong‐Neto, K. Choo, G. Christoff, C.‐Y. Chu, K. Ciupka, N. Conlon, C. Costa, T. Craig, P. Criado, I. Danilycheva, R. Darlenski, E. De Arruda Chaves, L. de Montjoye, M. S. Doutre, A. Du‐Thanh, D. Ebo, S. Elkhalifa, S. Elmariah, T. El‐Shanawany, L. F. Ensina, R. Ertaş, R. Fachini Jardim Criado, M. Ferrer, S. Ferrucci, J. S. Fok, D. Fomina, L. Fonacier, G. Fouda, I. Francescantonio, A. Fukunaga, C. A. Galvan Calle, E. Garcia, K. Gáspár, A. Gelincik, S. Geng, K. Godse, M. Gonçalo, M. Gotua, C. Grattan, M. Grosber, G. Guidos Fogelbach, M. Guilarte, R. Guillod, E. Hamelmann, J. Hawkes, K. Hayama, R. Heuer, M. Hide, W. Hoetzenecker, N. Inomata, H.‐R. Kang, A. Kaplan, A. Kapp, M. Karam, A. Kasperska‐Zajac, C. H. Katelaris, A. Kessel, M. Khoshkhui, B. Kim, T. Kinaciyan, E. Kocatürk, M. Kolacinska‐Flont, P. Kolkhir, G. N. Konstantinou, M. Kosnik, D. Krasowska, K. Kulthanan, M. S. Kumaran, I. Kuprys‐Lipinska, M. Labrador, J. I. Larco, D. Larenas‐Linnemann, E. Latysheva, E. Lazaridou, P. H. Li, H. Lima, U. Lippert, M. Magerl, M. Makris, J. Alves Marcelino, A. V. Marzano, I. Medina, R. Meshkova, D. Micallef, R. Mohammed Ali, C. G. Mortz, M. Munoz, H. N. G. Oude Elberink, A. Nakonechna, I. Nasr, A. Nast, E. Netchiporouk, E. Nettis, S. Nieto, I. Ogueta Canales, T.‐L. Okas, R. L. Orfali, E. Özkaya, C. Parisi, A. Pennitz, R. Pawankar, M. P. Pereira, J. Peter, E. Petkova, P. D. Pigatto, I. Podder, T. Popov, G. Porebski, P. Pyatilova, G. D. Ramon, H. A. Ratti Sisa, M. Recto, K. Ress, K. Ridge, M. Riedl, C. Ritchie, N. Rosario Filho, I. Rosmaninho, M. Rudenko, M. Rukhadze, K. Rutkowski, V. Sabato, U. M. Sahiner, S. Saini, F. Saleh Al Sabbagh, A. Salman, F. Salvo, J. Sanchez, A. Santucci, S. Schliemann, P. Schmid‐Grendelmeier, B. E. Sekerel, F. Serpa, F. Sheikh, J. Sheikh, H. Shendi, F. Siebenhaar, M. Sonomjamts, A. Soria, B. Sousa Pinto, M. Staevska, P. Staubach, M. Stephan, K. Stevanovic, L. Stingeni, M. Stobiecki, Ö. Su Küçük, G. Sussman, A. Szegedi, S. Takahagi, A. Tanaka, N. Teovska Mitrevska, S. F. Thomsen, E. Toubi, F. Tsatsou, M. Turk, Z. Vadasz, A. Valerieva, S. Valle, M. v. Doorn, B. Veleiro Perez, C. E. Vera Ayala, C. Vestergaard, R. J. Vieira, C. W. Maruta, B. Wedi, R. N. Werner, E. W. Y. Yap, P. Xepapadaki, Y. Xiang, Y.‐M. Ye, P. Yong, G. Yosipovitch, A. Z. J. Zalewska‐Janowska, C. Zeyen, Z. Zhao, M. Metz, A. M. Giménez‐Arnau   +221 more
wiley   +1 more source

Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy [PDF]

, 2023
Background: The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma.
Adlington, Timothy, Bardelas, Jose, Beck, Ekkehard, Beghé, Bianca, Berger, William, Bjerrum, Anne Sofie, Blanc, François-Xavier, Blasi, Francesco, Bobolea, Irina Diana, Bonnet, Reiner, Bonniaud, Philippe, Bourdin, Arnaud, Brehler, Randolf, Burden, Annie, Calhoun, William, Campbell, Edward, Canonica, Giorgio Walter, Caruso, Cristiano, Chanez, Pascal, Chapman, Kenneth, Chaudhuri, Rekha, Cheema, Amarjit, Cherry, William Brett, Chupp, Geoffrey, Clore, Lee, Cole, Jeremy, Conemans, Lennart, Corsico, Angelo Guido, Cosio, Borja, Crimi, Nunzio, Curiac, Dan, Darveaux, Jared, Davis, Benjamin, de la Cruz, Luis, de Luiz Martinez, Gustavo, de Luiz, Gustavo, Deleon, Samuel, Deschampheleire, Maud, Deslee, Gaetan, Devouassoux, Gilles, Didier, Alain, Doberer, Daniel, Dorscheid, Delbert, Douadi, Youcef, Echave-Sustaeta, Jose Maria, Fakih, Faisal, Fernandez, Ana Gomez-Bastero, Fost, David, Fry, Stephanie, Gall, Xavier Muñoz, Garcia Gil, Esther, Garcia Rivero, Juan Luis, Garcia, Ismael Ali, Girodet, Pierre-Olivier, Gleiber, Wolfgang, Gonzalez Perez, Ruperto, Gonzalez, Erika, Goodman, Brad, Goss, Deborah, Guarnieri, Gabriella, Guerrero, Raquel Morillo, Hajal, Rizan, Harris, James, Harrison, Tim, Heidarian Raissy, Hengameh, Henriquez Santa, Aythamy, Hilberg, Ole, Hill, David, Himpe, Ulrike, Holguin, Fernando, Holters, Jurgen, Hussain, Iftikhar, Ilowite, Jonathan, Jarratt, Mikell, Kao, Neil, Kashyap, Ravindra, Kaufman, David, Keeling, Nanna, Kilpeläinen, Maritta, Kronsbein, Juliane, Kureishy, Shahrukh, Kwiatek, Justin, Lacedonia, Donato, Langeveld, Bas, Larivee, Pierre, Leflein, Jeffrey, Lehmann, Sverre, Leong, Mila, Leuppi, Joerg, Lin, Robert, Louis, Renaud, Lugogo, Njira, Mahay, Guillaume, Mansur, Adel, Marcus, Michael, Marshall, Gailen, Martinot, Jean Benoit, Maselli Caceres, Diego Jose, Mehta, Hemalini, Mehta, Vinay, Melloni, Boris, Menzella, Francesco, Micheletto, Claudio, Milanese, Manlio, Millard, Mark, Milstone, Aaron, Moore, Wendy, Moss, Mark, Mozo, Paloma Campo, Mumneh, Nayla, Nasser, Shuaib, Nocent Ejnaini, Cecilia, Nordstrom, Monica, Olivenstein, Ronald, Palumbo, Michael, Pan, Carmen Vidal, Papi, Alberto, Peche, Rudi, Pelaia, Girolamo, Peveri, Silvia, Pfeffer, Paul, Philteos, George, Pini, Laura, Pison, Christophe, Pleskow, Warren, Pohl, Wolfgang, Poirier, Claude, Pradelli, Johana, Prenner, Bruce, Puppala, Dileep, Ramos Gonzalez, Jacinto, Ramsey, Clare, Randolph, Christopher, Reibman, Joan, Ribas, Christian Domingo, Rivera, Carlos Martinez, Robinette, Emory, Rodicio, Ileana, Rodriguez Hermosa, Juan Luis, Rolf, Jeffrey, Roux, Pauline-Marie, Santus, Pierachille, Saralaya, Dinesh, Schaum, Thomas, Schmid-Grendelmeier, Peter, Schreiber, Jens, Schuette, Wolfgang, Schulz, Christian, Scichilone, Nicola, Senna, Gianenrico, Short, Philip, Sikand, Vinay, Skowasch, Dirk, Smit, Arthur, Soong, Weily, Soto Campos, Jose Gregorio, Spadaro, Giuseppe, St. John, Roy, Staaks, Gerald, Stenfors, Nikolai, Steven, Gary, Subramaniam, Vijay, Sumino, Kaharu, Sussman, Robert, Sztejman, Eric, Taillé, Camille, Tan, Ricardo, Tanus, Tonny, Taube, Christian, Tellez, Sergio Campos, Tiotiu, Iuliana-Angelica, Titlestad, Ingrid, Tunsäter, Alf, van Veen, Helena, Vinge, Ines, von Garnier, Christophe, Walker, Brandie, Welte, Tobias, Wenzel, Sally, Willem van den Berg, Jan, Zafra, Heidi   +180 more
core   +2 more sources

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort

Journal of Asthma and Allergy, 2018
Michel Aubier,1–4 Gabriel Thabut,1–3,5 Caroline Fabry-Vendrand6 1Inserm UMR1152, Physiopathology and Epidemiology of Respiratory Diseases, Paris, France; 2Faculty of Medicine, Paris Diderot University, Paris, France; 3Laboratory of Excellence,
Aubier M, Thabut G, Fabry-Vendrand C
doaj  

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Frontiers in Immunology, 2023
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and ...
Santi Nolasco, Santi Nolasco, Andrea Portacci, Raffaele Campisi, Enrico Buonamico, Corrado Pelaia, Alida Benfante, Massimo Triggiani, Giuseppe Spadaro, Maria Filomena Caiaffa, Giulia Scioscia, Aikaterini Detoraki, Giuseppe Valenti, Francesco Papia, Alessandra Tomasello, Nunzio Crimi, Nicola Scichilone, Girolamo Pelaia, Giovanna Elisiana Carpagnano, Claudia Crimi, Claudia Crimi   +20 more
doaj   +1 more source

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

Allergy, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi, Sietze Reitsma, Valérie Hox, Simon Gane, Philippe Gevaert, Juan Maza‐Solano, Alma Helevä, Ida Sulku, Kaisa Santala, Iiris Kangasniemi, Ludger Klimek, Adam Chaker, Aspasia Karavelia, Michael Rudenko, Oliver Pfaar, Laura Van Gerven, Shaari Ariana, Michele Schiappoli, Marie Lundberg, Jan Hagemann, Ibon Eguíluz‐Gracia, Andre Moreira   +21 more
wiley   +1 more source

Early and Sustained Asthma Control and Remission in Real‐World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC‐2

Clinical &Experimental Allergy, EarlyView.
Real‐world patients with severe eosinophilic asthma treated with benralizumab showed early and sustained improvements in symptoms. Clinically meaningful improvements began as early as one week after benralizumab initiation, regardless of previous biologic use, and further improved over the following year.
Erika Penz, Thomas Rothe, Lieven Dupont, Trung N. Tran, Andrew Menzies‐Gow, Anat Shavit, David Cohen, Tanja Plate, Sheena Kayaniyil, An Herreman, Claudio Schuoler, Benjamin Emmanuel, Marek Lommatzsch   +12 more
wiley   +1 more source

Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma

Journal of Asthma and Allergy, 2022
Saad AlShareef,1 Christine F McDonald,2– 4 Joy Lee2,5 1Department of Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317-4233, Saudi Arabia; 2Department of Respiratory and Sleep Medicine, Austin Health ...
AlShareef S, McDonald CF, Lee J
doaj